PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone

被引:24
作者
Akyol, F
Ozyigit, G [1 ]
Selek, U
Karabulut, E
机构
[1] Hacettepe Univ, Fac Med, Dept Radiat Oncol, TR-06100 Ankara, Turkey
[2] Hacettepe Univ, Fac Med, Dept Biostat, TR-06100 Ankara, Turkey
关键词
prostate cancer; radiotherapy; androgen deprivation; PSA bounce;
D O I
10.1016/j.eururo.2005.04.007
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To assess the factors effecting PSA bounce and to identify any possible relationship with biochemical control after 3-D conformal radiotherapy (3D-CRT) and total androgen deprivation (TAD) for prostate cancer by evaluating four previously described PSA bounce definitions. Methods: Between January 1998 and January 2001, 83 consecutive patients with clinically localized prostate cancer were treated by 3D-CRT with neoadjuvant 3 months and/or 6 months adjuvant TAD. All patients had a pretreatment PSA level, at least eight post-external beam radiotherapy (EBRT) PSA and testosterone levels and minimum two years of follow-up. Total radiotherapy dose was 73.6 Gy at ICRU reference point. Four previous definitions of PSA bounce were used: Critz definition (>= 0.1 ng/mL), Cavanagh definition (>= 0.2 ng/mL), Hanlon definition (> 0.4 ng/mL) and Rosser definition (>= 0.5 ng/mL) according to original methodology performed to report PSA bounce. Biochemical failure was defined in accordance with the ASTRO consensus guidelines. Results: The median follow-up time was 40 months. PSA bounce was recorded as follows: Critz definition, 33 patients (40%); Cavanagh definition, 21 patients (25%); Hanlon definition, 11 patients (13%); and Rosser definition, 7 patients (8%). In multivariate analysis, pre-EBRT PSA level and the duration of TAD for Critz definition; age, pre-EBRT PSA and the duration of TAD for Cavanagh definition; age and duration of TAD for Hanlon definition; age and pre-biopsy PSA for Rosser definition were significant independent prognostic factors determining PSA bounce. A significant increase of mean testosterone level in bouncers was detected at the 6th-9th and 18th-21st months. PSA bounce did not predict for PSA failure in multivariate analysis. Conclusions: We observed no correlation between biochemical failure and PSA bounce. The longer duration of TAD and older age were found to be inversely proportional with PSA bouncing in this cohort. Notably, recovery of testosterone might cause PSA bouncing. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:40 / 45
页数:6
相关论文
共 26 条
[1]   TESTICULAR DOSES IN DEFINITIVE RADIATION-THERAPY FOR LOCALIZED PROSTATE-CANCER [J].
AMIES, CJ ;
MAMEGHAN, H ;
ROSE, A ;
FISHER, RJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 32 (03) :839-846
[2]  
Cavanagh W, 2000, Semin Urol Oncol, V18, P160
[3]  
Cox JD, 1997, INT J RADIAT ONCOL, V37, P1035
[4]   Post-treatment PSA ≤0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques [J].
Critz, FA ;
Williams, WH ;
Holladay, CT ;
Levinson, AK ;
Benton, JB ;
Holladay, DA ;
Schnell, FJ ;
Maxa, LS ;
Shrake, PD .
UROLOGY, 1999, 54 (06) :968-971
[5]   Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: The relationship to patient age [J].
Critz, FA ;
Williams, WH ;
Levinson, AK ;
Benton, JB ;
Schnell, FJ ;
Holladay, CT ;
Shrake, PD .
JOURNAL OF UROLOGY, 2003, 170 (05) :1864-1867
[6]   Time to achieve a prostate specific antigen nadir of 0.2 ng./ml. after simultaneous irradiation for prostate cancer [J].
Critz, FA .
JOURNAL OF UROLOGY, 2002, 168 (06) :2434-2438
[7]   The PSA nadir that indicates potential cure after radiotherapy for prostate cancer - Editorial comment [J].
Klein, EA ;
Kupelian, PJ .
UROLOGY, 1997, 49 (03) :326-326
[8]   Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer [J].
Critz, FA ;
Williams, WH ;
Benton, JB ;
Levinson, AK ;
Holladay, CT ;
Holladay, DA .
JOURNAL OF UROLOGY, 2000, 163 (04) :1085-1089
[9]  
Dearnaley DP, 1999, J UROLOGY, V162, P170, DOI 10.1097/00005392-199907000-00057
[10]  
FLEMING I, 1997, AJCC CANC STAGING MA, P47